drugset / Trial / NCT06545201
RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
At present, there is an urgent need for new drugs for kirsten rat sarcoma viral oncogene (KRAS) mutant tumors in clinic. Preclinical studies support the specificity, safety and anti-tumor activity of RE001. Previous similar studies suggest the feasibility of T cell receptor engineered T cell therapy (TCR-T) treatment, and measures have been taken to ensure the safe administration of RE001 and the close monitoring and management of adverse events. To sum up, RE001 has controllable safety and anti-tumor activity on KRAS mutant solid tumor, which can be preliminarily studied to provide support for clinical research of patients with advanced solid tumor.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2026-04-01
- Completion
- 2027-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RE001 | Cell therapy | 4e+09 cells | Other |
| Subject | RE001 | Cell therapy | 8e+09 cells | Other |
| Subject | RE001 | Cell therapy | 1.6e+10 cells | Other |
Indications
No indication recorded.